Saratoga Health & Biotechnology Fund

2 / 5 Stars
2 1 5 1 4
Zacks Investment Research
5 (Strong Sell)
Standard & Poor's
3 / 5 Stars
A (Buy)

#24 in Health

U.S. News evaluated 33 Health Funds. Our list highlights the top-rated funds for long-term investors based on the ratings of leading fund industry researchers.

See all Saratoga funds

See full Health rankings

See more fund rankings


The fund has returned 29.36 percent over the past year, 17.05 percent over the past three years, 20.28 percent over the past five years, and 9.67 percent over the past decade.

Trailing Returns Updated 06.30.2014
Year to date 9.9%
1 Year 29.4%
3 Years (Annualized) 17.1%
5 Years (Annualized) 20.3%
10 Years (Annualized) 9.7%

See more SHPAX performance


The investment seeks long-term capital growth. The fund invests at least 80% of its total assets in equity securities of U.S. and foreign healthcare companies and biotechnology companies, regardless of their stock market value (or "market capitalization"). Equity securities include common stocks, preferred stocks, securities convertible into common stocks and warrants. Under adverse market conditions, it may also make temporary investments in investment grade debt securities. Such investment strategies could result in the Portfolio not achieving its investment objective. The fund is non-diversified.


Fees are Low compared to funds in the same category.
Saratoga Health & Biotechnology Fund has an expense ratio of 2.60 percent.

See more SHPAX fees


Risk is Low compared to funds in the same category according to Morningstar.

See more SHPAX risk